Core Viewpoint - Zhongyou Securities initiates coverage on Innovent Biologics (01801.HK) with a "Buy" rating, highlighting the company's leading position in the domestic oncology drug sector and its diverse pipeline that is expected to drive high growth in performance [1] Company Analysis - Innovent Biologics is recognized for its comprehensive pipeline layout in the oncology drug market, which is anticipated to support sustained high growth in revenue [1] - The company is projected to achieve net profits attributable to shareholders of 980 million, 1.58 billion, and 3.25 billion yuan for the years 2025, 2026, and 2027 respectively [1] - Corresponding price-to-earnings (PE) ratios are expected to be 162, 100, and 49 for the same years [1]
中邮证券：首次覆盖信达生物 给予买入评级